Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELOX III: Standard vs Chronomodulated XELOX in Metastatic Colorectal Cancer
NCT00212615Phase 3Completed
- Sponsor
- University Hospital Odense
- Start
- Feb 2004
- Primary completion
- Oct 2008
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of capecitabine, oxaliplatin in colorectal cancer (CRC), sponsored by University Hospital Odense. Started Feb 2004; status: completed.
02
Drugs
capecitabineoxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00212615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00212615.